Genome Editing and Biological Effects Testing Component

NIH RePORTER · NIH · U42 · $651,851 · view on reporter.nih.gov ↗

Abstract

Genome Editing and Biological Effects Testing PROJECT SUMMARY / ABSTRACT The overarching goal of the Genome Editing and Biological Effects Testing Component of the Center for Somatic Cell Genome Editing in Nonhuman Primates is to test delivery reagents and editing tools developed by investigators in wild-type, reporter, and disease models. Studies performed will address the efficiency, specificity, and safety of genome editing technologies, including the duration of editing activity, and the potential for inflammation and immunogenicity. Nonhuman primates will be provided through the Resource Component, and the Coordination Component will ensure studies are well managed and prioritized, with efficient data collection, analysis, and sharing. The Genome Editing and Biological Effects Testing Component will work directly with investigators and utilize demonstrated capabilities to test a range of viral and nonviral vectors and contribute to the acceleration of the translation of somatic cell genome editing technologies into treatments for human diseases. The Genome Editing and Biological Effects Testing Component will address the following Specific Aims: (1) Evaluate somatic cell genome editing across age groups in nonhuman primates, and (2) Assess biological effects, safety, and the potential for inflammation and immune responses in nonhuman primate models. The Genome Editing and Biological Effects Testing Component team has the expertise and flexibility to work with investigators to quantify any desired type of genome editing event (e.g., on-target, off-target, large rearrangements, duration of editing, cell specificity), and in any organ system, cell population, or age group. Paired with a robust Resource Component, and through the infrastructure of the UC Davis Genome Center, California National Primate Research Center, and Clinical and Translational Science Center, the Genome Editing and Biological Effects Testing Component will deliver the data needed to comprehensively assess the promise of new somatic cell genome editing technologies developed by investigators.

Key facts

NIH application ID
10911367
Project number
5U42OD035737-02
Recipient
UNIVERSITY OF CALIFORNIA AT DAVIS
Principal Investigator
DAVID J SEGAL
Activity code
U42
Funding institute
NIH
Fiscal year
2024
Award amount
$651,851
Award type
5
Project period
2023-09-01 → 2028-08-31